2023版ESMO临床实践指南:早期乳腺癌的诊断、治疗与随访(上篇) 在2023年12月13日,备受瞩目的《肿瘤学年鉴》(Annals of Oncology,影响因子:50.5)期刊在线发布了2023版ESMO早期乳腺癌临床实践指南——“Early breast cancer: ESMO Clinical Practic...
近年来,随着分子生物学、基因组学和药物基因组学的快速发展,早期乳腺癌的治疗正迅速向个体化精准医疗的方向发展。在2024年欧洲肿瘤内科学会乳腺癌大会(ESMO BC)上,来自德国慕尼黑大学医院乳腺癌中心的Nadia Harbeck博士发表了主题演讲《MAKI...
2、Nederlof I, et al. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). ESMO Congress 2024, LBA11 来源: https://dailyreporter.esmo.org/esmo-congress-2024/breast-cancer/early-stage-immunotherapy-significantly-prol...
[4]Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 Oct;32(10):1216-1235. [5]Early Breast Cancer Trialist...
Early breast cancer: Surgery and radiotherapy Early breast cancer: Systemic treatments Early detection, hereditary breast cancer and prevention Metastatic breast cancer Supportive care and survivorship Miscellaneous Late-breaking abstracts Late-breaking abstracts may be submitted for high quality, new research...
Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial 早期乳腺癌局部低剂量放疗与正常剂量放疗的对比:HypoG-01 III期UNICANCER试验的5年结果 讲者:Sofia Rivera (Villejuif, Cedex, France) ...
2、Nederlof I, et al. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). ESMO Congress 2024, LBA11 来源: https://dailyreporter.esmo.org/esmo-congress-2024/breast-cancer/early-stage-immunotherapy-significantly-prol...
2O - Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2− early breast cancer (EBC) NATALEE研究中亚洲与非亚洲患者疗效分析:使用瑞波西利(RIB)联合非甾体芳香化酶抑制剂(NSAI)治疗HR+/HE...
Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials 体重指数及其变化对早期乳腺癌患者生存结果的影响:基于BCIRG-001和BCIRG-005试验的个体水平数据的汇总分析 ...
[1]Oleg Gluz. LBA17 - Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial. https://cslide.ctimeetingtech.com/esmo2024/attendee...